{"hands_on_practices": [{"introduction": "A cornerstone of quantitative biology is the ability to mathematically describe how a gene's activity responds to an input signal, such as a drug or metabolite. This practice guides you through the first-principles derivation of the Hill function, a model that captures the sigmoidal, switch-like behavior of many biological systems. By modeling a ligand-activated transcription factor, you will develop a foundational tool for predicting and engineering the dose-response of therapeutic gene circuits [@problem_id:5065417].", "problem": "A translational synthetic biology team is designing a ligand-activated gene circuit to control therapeutic protein secretion in vivo. The circuit uses a transcription factor (TF) with $n$ identical ligand-binding sites that activates a promoter only when all $n$ sites are simultaneously occupied by a small-molecule ligand $L$. Assume the following biophysical scenario and modeling assumptions:\n\n- Binding of ligand to the TF follows the law of mass action and reaches rapid equilibrium on the timescale of transcriptional activation.\n- Cooperativity is concerted and strong, such that the promoter has two dominant functional states relevant to activation: an inactive state with zero bound ligand and an active state with all $n$ sites bound.\n- The macroscopic equilibrium association constant for forming the fully bound active complex is well-defined, and the effective dissociation constant $K_d$ is the ligand concentration at which the promoter occupancy is one-half.\n\nStarting only from these assumptions, derive the functional dependence of promoter occupancy $\\Theta(L)$ on the ligand concentration $L$, the Hill coefficient $n$, and the dissociation constant $K_d$. Then evaluate the occupancy for $K_d = 10$ nM, $L = 30$ nM, and $n = 2$. Express the final occupancy as a decimal number with no unit. If rounding were necessary, you would round to four significant figures, but in this case provide the exact value.", "solution": "We begin from the law of mass action and equilibrium statistical reasoning. Under the concerted, all-or-none cooperativity assumption, the promoter-TF-ligand system has two dominant activation-relevant states:\n\n1. An inactive state with zero ligand bound.\n2. An active state with $n$ ligands bound.\n\nLet the macroscopic association constant for forming the fully bound active complex be denoted by $K_n$, which has units of $\\mathrm{(concentration)}^{-n}$. The statistical weight of the inactive state is $1$ (reference), and the statistical weight of the active state is $K_n L^{n}$, where $L$ is the free ligand concentration. The binding polynomial (partition function) is then\n$$\nZ \\;=\\; 1 \\;+\\; K_n L^{n}.\n$$\nThe probability (occupancy) of the active state, which maps to promoter occupancy for activation, is the fraction of the active state's weight in the total:\n$$\n\\Theta(L) \\;=\\; \\frac{K_n L^{n}}{1 + K_n L^{n}}.\n$$\n\nNext, we connect $K_n$ to the effective dissociation constant $K_d$. By the definition of $K_d$, the promoter occupancy is one-half at $L = K_d$, that is\n$$\n\\Theta(K_d) \\;=\\; \\frac{K_n K_d^{n}}{1 + K_n K_d^{n}} \\;=\\; \\frac{1}{2}.\n$$\nSolving for $K_n K_d^{n}$ yields\n$$\nK_n K_d^{n} \\;=\\; 1 \\quad \\Rightarrow \\quad K_n \\;=\\; K_d^{-n}.\n$$\nSubstituting $K_n = K_d^{-n}$ into $\\Theta(L)$ gives\n$$\n\\Theta(L) \\;=\\; \\frac{K_d^{-n} L^{n}}{1 + K_d^{-n} L^{n}}\n\\;=\\;\n\\frac{L^{n}}{K_d^{n} + L^{n}}.\n$$\nThis is the Hill-type promoter occupancy function for a concerted cooperative activator with Hill coefficient $n$ and half-occupancy concentration $K_d$.\n\nWe now compute the occupancy for $K_d = 10$ nM, $L = 30$ nM, and $n = 2$. Using\n$$\n\\Theta(L) \\;=\\; \\frac{L^{n}}{K_d^{n} + L^{n}},\n$$\nwe have\n$$\n\\Theta(30\\ \\mathrm{nM}) \\;=\\; \\frac{(30)^{2}}{(10)^{2} + (30)^{2}}\n\\;=\\; \\frac{900}{100 + 900}\n\\;=\\; \\frac{900}{1000}\n\\;=\\; \\frac{9}{10}\n\\;=\\; 0.9.\n$$\nThe occupancy is dimensionless and, per the instructions, expressed as a decimal with no unit. No rounding is needed beyond the exact value.", "answer": "$$\\boxed{0.9}$$", "id": "5065417"}, {"introduction": "Building on the concept of a genetic switch, this exercise explores the dynamics of a complete circuit, where the therapeutic output results from a balance between production and clearance. You will model a common synthetic architecture—a circuit that represses protein production in response to a specific ligand—and calculate its steady-state output level. Mastering this type of analysis is essential for predicting how an engineered cell will perform in a complex biological environment and for tuning its therapeutic dose [@problem_id:5065415].", "problem": "An engineered probiotic chassis is designed to secrete a therapeutic protein with concentration denoted by $X$ in response to a disease-associated small-molecule ligand denoted by $L$. The genetic control architecture implements repression such that the production flux decreases with increasing $L$ according to a Hill-type repression function derived from receptor–ligand equilibrium occupancy. The dynamics of $X$ are modeled by the ordinary differential equation (ODE) $$\\frac{dX}{dt}=\\frac{\\alpha}{1+\\left(\\frac{L}{K_{d}}\\right)^{n}}-\\delta\\,X,$$ where $\\alpha$ is the maximal synthesis rate, $K_{d}$ is the dissociation constant that sets the half-maximal ligand scale, $n$ is the Hill coefficient capturing effective cooperativity of repression, and $\\delta$ is the first-order loss constant that aggregates proteolysis and washout. In translational medicine, steady-state dosing levels determine the therapeutic window, so the operating point $X^{*}$ is defined by the steady-state condition $\\frac{dX}{dt}=0$ based on mass balance.\n\nStarting from the definitions of receptor–ligand equilibrium with Hill-type repression and first-order loss kinetics, determine the steady-state concentration $X^{*}$ for the parameter values $\\alpha=100$ (nanomolar per minute, nM/min), $K_{d}=50$ (nanomolar, nM), $n=1$, $L=25$ (nanomolar, nM), and $\\delta=0.1$ (per minute, min$^{-1}$). Express your final answer in nanomolar (nM) and round your answer to four significant figures.", "solution": "The dynamics of the therapeutic protein concentration, $X$, are described by the given ordinary differential equation (ODE):\n$$ \\frac{dX}{dt}=\\frac{\\alpha}{1+\\left(\\frac{L}{K_{d}}\\right)^{n}}-\\delta\\,X $$\nHere, $\\alpha$ is the maximal synthesis rate, $K_{d}$ is the dissociation constant, $n$ is the Hill coefficient, $L$ is the ligand concentration, and $\\delta$ is the first-order loss constant.\n\nThe steady-state concentration, denoted as $X^{*}$, is achieved when the system reaches equilibrium, i.e., when the rate of change of the protein concentration is zero. This condition is mathematically defined as $\\frac{dX}{dt}=0$.\n\nBy setting the derivative to zero and substituting $X$ with $X^{*}$, we obtain the algebraic equation for the steady-state:\n$$ 0 = \\frac{\\alpha}{1+\\left(\\frac{L}{K_{d}}\\right)^{n}} - \\delta X^{*} $$\n\nTo find the expression for $X^{*}$, we rearrange the equation:\n$$ \\delta X^{*} = \\frac{\\alpha}{1+\\left(\\frac{L}{K_{d}}\\right)^{n}} $$\nIsolating $X^{*}$ yields the general solution for the steady-state concentration:\n$$ X^{*} = \\frac{\\alpha}{\\delta\\left(1+\\left(\\frac{L}{K_{d}}\\right)^{n}\\right)} $$\n\nThe problem provides the following specific values for the parameters:\n- $\\alpha = 100 \\, \\text{nM/min}$\n- $K_{d} = 50 \\, \\text{nM}$\n- $n = 1$\n- $L = 25 \\, \\text{nM}$\n- $\\delta = 0.1 \\, \\text{min}^{-1}$\n\nWe substitute these values into the expression for $X^{*}$:\n$$ X^{*} = \\frac{100}{0.1\\left(1+\\left(\\frac{25}{50}\\right)^{1}\\right)} $$\nFirst, we evaluate the term inside the parentheses:\n$$ \\frac{25}{50} = 0.5 $$\nThe expression simplifies to:\n$$ X^{*} = \\frac{100}{0.1\\left(1+0.5\\right)} $$\n$$ X^{*} = \\frac{100}{0.1\\left(1.5\\right)} $$\n$$ X^{*} = \\frac{100}{0.15} $$\nPerforming the division gives the exact value of $X^{*}$:\n$$ X^{*} = \\frac{2000}{3} \\approx 666.666... \\, \\text{nM} $$\nThe problem requires the final answer to be rounded to four significant figures. The first four significant digits are $6$, $6$, $6$, $6$. The fifth digit is $6$, which is greater than or equal to $5$, so we round up the fourth significant digit.\n$$ X^{*} \\approx 666.7 \\, \\text{nM} $$", "answer": "$$\\boxed{666.7}$$", "id": "5065415"}, {"introduction": "A critical challenge in translational medicine, particularly in oncology, is designing therapies that precisely target diseased cells while sparing healthy tissue. This advanced problem demonstrates how synthetic biology addresses this challenge by engineering logical \"AND\" gates into therapeutic cells. You will employ a probabilistic framework to quantify the expected safety of a dual-antigen recognition system, reflecting a cutting-edge strategy used to minimize off-tumor toxicity in advanced cell therapies [@problem_id:5065343].", "problem": "A translational synthetic biology therapy uses a two-step AND logic gate to minimize off-tumor toxicity: a synthetic Notch receptor (synNotch) specific to antigen $A$ induces expression of a Chimeric Antigen Receptor (CAR) specific to antigen $B$, and cytotoxicity is executed only when the target cell presents both antigens above prevalidated therapeutic thresholds. Consider a healthy tissue compartment in which antigen presence above threshold on a randomly sampled cell is modeled by two Bernoulli random variables $A$ and $B$, where $A=1$ denotes antigen $A$ is present above threshold and $B=1$ denotes antigen $B$ is present above threshold. The measured marginal background expression frequencies are $f_A = \\Pr(A=1)$ and $f_B = \\Pr(B=1)$, with $0  f_A  1$, $0  f_B  1$. To capture realistic co-expression dependence in healthy tissues, suppose the $2 \\times 2$ joint distribution of $(A,B)$ has odds ratio $\\omega  0$, $\\omega \\neq 1$, defined by $\\omega = \\dfrac{p_{11} p_{00}}{p_{10} p_{01}}$, where $p_{ij} = \\Pr(A=i, B=j)$. Under an ideal AND gate that triggers only when both antigens are present above threshold, the expected false positive rate is the probability that a randomly sampled healthy cell co-expresses both antigens above threshold, i.e., $\\Pr(A=1,B=1)$.\n\nStarting from the axioms of probability and the definition of odds ratio, derive the closed-form analytic expression for the expected false positive rate in terms of $f_A$, $f_B$, and $\\omega$ only. Provide your final answer as a single closed-form analytic expression. No numerical approximation or rounding is required.", "solution": "The problem asks for a closed-form analytic expression for the expected false positive rate, which is defined as the joint probability $\\Pr(A=1, B=1)$. Let us denote this probability by $p_{11}$. The given information includes the marginal probabilities $f_A = \\Pr(A=1)$ and $f_B = \\Pr(B=1)$, and the odds ratio $\\omega$.\n\nThe joint probability distribution of the two Bernoulli random variables $(A,B)$ is given by the four probabilities $p_{ij} = \\Pr(A=i, B=j)$ for $i, j \\in \\{0, 1\\}$. These four probabilities must sum to $1$.\n$$p_{00} + p_{01} + p_{10} + p_{11} = 1$$\n\nThe marginal probabilities are related to the joint probabilities as follows:\n$$f_A = \\Pr(A=1) = p_{10} + p_{11}$$\n$$f_B = \\Pr(B=1) = p_{01} + p_{11}$$\n\nFrom these relationships, we can express $p_{10}$ and $p_{01}$ in terms of $p_{11}$ and the known marginals $f_A$ and $f_B$:\n$$p_{10} = f_A - p_{11}$$\n$$p_{01} = f_B - p_{11}$$\n\nNow, we can express $p_{00}$ in terms of $p_{11}$, $f_A$, and $f_B$ by using the axiom that the total probability is $1$:\n$$p_{00} = 1 - p_{11} - p_{10} - p_{01}$$\nSubstituting the expressions for $p_{10}$ and $p_{01}$:\n$$p_{00} = 1 - p_{11} - (f_A - p_{11}) - (f_B - p_{11})$$\n$$p_{00} = 1 - f_A - f_B + p_{11}$$\n\nWe now have all four joint probabilities expressed in terms of the single unknown $p_{11}$ and the given parameters $f_A$ and $f_B$. The problem provides the definition of the odds ratio $\\omega$:\n$$\\omega = \\frac{p_{11} p_{00}}{p_{10} p_{01}}$$\n\nWe substitute the expressions for $p_{ij}$ into the odds ratio formula to obtain an equation solely for $p_{11}$:\n$$\\omega = \\frac{p_{11} (1 - f_A - f_B + p_{11})}{(f_A - p_{11})(f_B - p_{11})}$$\n\nThe problem states that $\\omega \\neq 1$, so we can rearrange this equation into a quadratic form.\n$$\\omega (f_A - p_{11})(f_B - p_{11}) = p_{11}(1 - f_A - f_B + p_{11})$$\nExpanding both sides:\n$$\\omega (f_A f_B - f_A p_{11} - f_B p_{11} + p_{11}^2) = p_{11} - f_A p_{11} - f_B p_{11} + p_{11}^2$$\n$$\\omega f_A f_B - \\omega(f_A + f_B)p_{11} + \\omega p_{11}^2 = (1 - f_A - f_B)p_{11} + p_{11}^2$$\n\nWe group terms by powers of $p_{11}$ to form a standard quadratic equation of the form $ax^2+bx+c=0$ with $x=p_{11}$:\n$$(\\omega - 1)p_{11}^2 - [\\omega(f_A + f_B) + (1 - f_A - f_B)]p_{11} + \\omega f_A f_B = 0$$\nThe coefficient of the linear term can be simplified:\n$$-[\\omega(f_A + f_B) + 1 - f_A - f_B] = -[(\\omega-1)(f_A+f_B) + 1]$$\nThus, the quadratic equation for $p_{11}$ is:\n$$(\\omega - 1)p_{11}^2 - [1 + (\\omega - 1)(f_A + f_B)]p_{11} + \\omega f_A f_B = 0$$\n\nWe can solve this for $p_{11}$ using the quadratic formula, $p_{11} = \\frac{-b \\pm \\sqrt{b^2 - 4ac}}{2a}$, with:\n$a = \\omega - 1$\n$b = -[1 + (\\omega - 1)(f_A + f_B)]$\n$c = \\omega f_A f_B$\n\nSubstituting these coefficients into the formula gives:\n$$p_{11} = \\frac{[1 + (\\omega - 1)(f_A + f_B)] \\pm \\sqrt{[1 + (\\omega - 1)(f_A + f_B)]^2 - 4(\\omega - 1)\\omega f_A f_B}}{2(\\omega - 1)}$$\n\nThis equation yields two possible solutions for $p_{11}$. We must select the one that is physically and probabilistically correct. The case of statistical independence, where $A$ and $B$ are uncorrelated, corresponds to an odds ratio of $\\omega=1$. In this case, the joint probability $p_{11}$ must equal the product of the marginal probabilities, $p_{11} = f_A f_B$. Although the problem specifies $\\omega \\neq 1$, we can determine the correct root by examining the limit as $\\omega \\to 1$.\n\nLet's analyze the numerator. As $\\omega \\to 1$, the term $1 + (\\omega - 1)(f_A + f_B)$ approaches $1$. The discriminant, $\\Delta = [1 + (\\omega - 1)(f_A + f_B)]^2 - 4(\\omega - 1)\\omega f_A f_B$, approaches $1^2 - 0 = 1$. The numerator thus approaches $1 \\pm 1$. The denominator, $2(\\omega-1)$, approaches $0$.\n\nIf we choose the '+' sign, the numerator approaches $2$, and the expression diverges. This is not a physically meaningful result.\nIf we choose the '-' sign, the numerator approaches $1-1=0$, leading to an indeterminate form $0/0$. We can resolve this using L'Hôpital's rule. Let $N(\\omega) = 1 + (\\omega - 1)(f_A + f_B) - \\sqrt{\\Delta(\\omega)}$ and $D(\\omega) = 2(\\omega-1)$.\nThe limit is $\\lim_{\\omega\\to 1} \\frac{N'(\\omega)}{D'(\\omega)}$.\n\nThe derivative of the denominator is $D'(\\omega) = 2$.\nThe derivative of the numerator is $N'(\\omega) = (f_A + f_B) - \\frac{1}{2\\sqrt{\\Delta(\\omega)}} \\Delta'(\\omega)$.\nFirst, we find $\\Delta'(\\omega)$:\n$\\Delta'(\\omega) = \\frac{d}{d\\omega} \\left( [1 + (\\omega-1)(f_A+f_B)]^2 - 4(\\omega^2-\\omega)f_A f_B \\right)$\n$\\Delta'(\\omega) = 2[1 + (\\omega-1)(f_A+f_B)](f_A+f_B) - (8\\omega - 4)f_A f_B$\nEvaluating at $\\omega=1$:\n$\\Delta'(1) = 2[1](f_A+f_B) - (8-4)f_A f_B = 2(f_A+f_B) - 4f_A f_B$.\nNow, we evaluate $N'(1)$, noting that $\\Delta(1)=1$:\n$N'(1) = (f_A+f_B) - \\frac{1}{2\\sqrt{1}} [2(f_A+f_B) - 4f_A f_B] = (f_A+f_B) - (f_A+f_B - 2f_A f_B) = 2f_A f_B$.\n\nApplying L'Hôpital's rule:\n$$\\lim_{\\omega\\to 1} p_{11} = \\frac{N'(1)}{D'(1)} = \\frac{2f_A f_B}{2} = f_A f_B$$\nThis confirms that the solution with the negative sign is the correct one, as it converges to the expected value for independent variables.\n\nTherefore, the closed-form analytic expression for the expected false positive rate, $p_{11}$, is:\n$$p_{11} = \\frac{1 + (\\omega - 1)(f_A + f_B) - \\sqrt{[1 + (\\omega - 1)(f_A + f_B)]^2 - 4\\omega(\\omega - 1)f_A f_B}}{2(\\omega - 1)}$$", "answer": "$$\\boxed{\\frac{1 + (\\omega - 1)(f_A + f_B) - \\sqrt{[1 + (\\omega - 1)(f_A + f_B)]^{2} - 4\\omega(\\omega - 1)f_A f_B}}{2(\\omega - 1)}}$$", "id": "5065343"}]}